Eli Lilly (LLY) on Friday announced that the U.S. FDA granted full approval for an all-oral regimen containing its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for breast cancer.
Specifically, the approval clears the combo for